• PrintPrint
  • Share
  • Text Size: A | A | A

New Clinical Trial for Pancreatic Cancer Patients at DeKalb Medical

January 18, 2012

Researchers seeking local patients for study of promising therapy

Atlanta, GA -- DeKalb Medical announces the availability of a clinical trial for patients with previously untreated Stage IV pancreatic cancer. The hospital's cancer center is actively seeking appropriate patients for the study, which can lead to a potential new therapy. 

"Traditionally with pancreatic cancer is a disease with a short median survival; this drug promises to improve patient outcome. We're excited to be working with Georgia CORE (Center for Oncology Research and Education) trials which allow us to offer new therapies to our patients," said hematologist-oncologist Jayanthi "Dr. Jay " Srinivasiah, M.D. 

"Pancreatic cancer remains the fourth leading cause of cancer death in the United States with few proven therapeutic options,” adds Nancy M. Paris, president and CEO of Georgia CORE. "This is a disease where novel strategies are needed urgently, particularly for patients in the advanced setting."

All patients enrolled in this clinical trial will receive the standard chemotherapy used to treat pancreatic cancer and some will receive the chemotherapy in combination with a novel monoclonal antibody called bavituximab. "In prior clinical studies, bavituximab in combination with chemotherapy has demonstrated promising tumor response and survival for cancer patients when compared to separate studies using chemotherapy alone," said Andrew W. Pippas, M.D., of the John B. Amos Cancer Center who will serve as the Principal Investigator for the five trial sites in Georgia. "As with all clinical trials, patients will undergo comprehensive consultation with medical professionals regarding the drug and how it will impact diagnosis and treatment," he added.

DeKalb Medical is one of a handful of research centers throughout the nation offering this trial. Clinical trials can help determine the tested drug’s efficacy and safety, and may lead to eventual approval of the agent by the United States Food and Drug Administration (FDA). To enroll in this trial, patients should contact DeKalb Medical's Cancer Center at 404.501.7654.

For more information on Georgia CORE visit www.georgiacore.org. For more information on DeKalb Medical visit www.dekalbmedical.org.

About DeKalb Medical Cancer Center

DeKalb Medical continues to be a leader in Atlanta in oncology research and treatment. The Commission on Cancer of the American College of Surgeons validated the excellence of our cancer program in June 2010 by granting a three-year approval with commendation to DeKalb Medical as a community comprehensive cancer center. In addition, DeKalb Medical also received the Outstanding Achievement Award from the Commission on Cancer in 2007 for exceeding the standards set out by the Commission. Only 20 percent of hospitals in the United States have been awarded the Outstanding Achievement Award. Join us on Facebook at www.facebook.com/dekalbmedicalcancercenter.

Media Contact:

Tori Vogt MBA

tori.vogt@dekalbmedical.org, 404.501.2885

2701 North Decatur Road Decatur, GA 30033
404.501.1000
Patient Inquiries: 404.501.5200

Privacy Policy
Social Media Policy